Biogen Inc. (BIIB) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| GAAP cost of sales (% of total revenue) | 27.00 percent | FY2026-Q1 |
| Non-GAAP cost of sales (% of total revenue) | 25.00 percent | FY2026-Q1 |
| Biogen Non-GAAP Diluted EPS | 3.57 USD_per_share | FY2026-Q1 |
| ZURZUVAE revenue | 66M | FY2025-Q4 |
| Free cash flow (Free Cash Flow) | 468M | FY2025-Q4 |
| Biosimilars revenue | 197M | FY2025-Q3 |
| Revenue from anti-CD20 therapeutic programs | 494M | FY2025-Q3 |
| Total rare disease revenue | 533M | FY2025-Q3 |
| Contract manufacturing, royalty and other revenue | 151M | FY2025-Q3 |
Back to BIIB overview · BIIB earnings · BIIB holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.